Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.36 |
| ▸ | MGLL | Q99685 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21275957 | 0.93 | PTGS1 (0.46) | PTGS1PTGS2CASP1HDAC1MGLL | |
| SCHEMBL17722905 | 0.92 | PTGS1 (0.49) | PTGS1PTGS2CASP1HDAC1MGLL | |
| SCHEMBL20889003 | 0.92 | PTGS1 (0.40) | PTGS1PTGS2CASP1HDAC1MGLL | |
| SCHEMBL22698754 | 0.91 | PTGS1 (0.48) | PTGS1PTGS2CASP1HDAC1MGLL | |
| SCHEMBL19681331 | 0.91 | PTGS1 (0.50) | PTGS1PTGS2CASP1HDAC1MGLL | |
| SCHEMBL22668936 | 0.89 | PTGS1 (0.46) | PTGS1PTGS2CASP1HDAC1MGLL | |
| SCHEMBL23256415 | 0.87 | PTGS1 (0.41) | PTGS1PTGS2 | |
| SCHEMBL23420959 | 0.85 | FAP (0.37) | PTGS1PTGS2 | |
| SCHEMBL20887736 | 0.85 | FAP (0.37) | PTGS1PTGS2 | |
| SCHEMBL20670908 | 0.85 | PTGS1 (0.46) | PTGS1PTGS2CASP1HDAC1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045480-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190105328-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2019-04-11 | — | — | US | disclosed |
| US-10188660-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10011657-B2 | Anti-CS1 antibodies and antibody drug conjugates | ABBVIE BIOTHERAPEUTICS INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | PTGS1 4828/4885PTGS2 4820/4885CASP1 3520/4885 |
| US-11045480-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | LRRC59, LRRC47, HACD3 | PTGS1 4828/4885PTGS2 4820/4885CASP1 3520/4885 |
| US-20190105328-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | PTGS1 4828/4885PTGS2 4820/4885CASP1 3520/4885 |
| US-10011657-B2 | Anti-CS1 antibodies and antibody drug conjugates | CD47, CSGALNACT1, CSE1L | PTGS1 4460/4885PTGS2 4772/4885CASP1 3385/4885 |
| US-10188660-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | LRRC59, LRRC47, HACD3 | PTGS1 4828/4885PTGS2 4820/4885CASP1 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.